GLP-1 receptor agonist treatment reduces bone mineral density.
- Current status
- Preliminary signalEvidence stable · Bone
- Why
- In S-LiTE, liraglutide alone was associated with lower hip and spine BMD than exercise alone after a year of weight maintenance; combining exercise with liraglutide preserved BMD. Fracture outcomes are not available. Effect likely reflects weight loss rather than a direct drug effect, but this was not separated.
- What would change it
- Fracture-outcome data or BMD trials in adults over 60.
A weight-matched comparison isolating drug effect on bone. - Linked studies
- 1 · 1 supports
- Last updated
- Sep 13, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
01The evidence
The evidence, sorted by what it shows
Supports (1)
- Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical TrialRandomized trial · 2024 · Study tier 2 · Different population · Harm direction · Partly industry funded
S-LiTE secondary analysis (n=195, age ~43, BMI ~37): liraglutide alone lost BMD relative to exercise; combination preserved BMD.
02History
How this assessment has changed
- Preliminary signalSep 13, 2026 · Evidence stable
initial curated status